Covington Advises Eikon Therapeutics on $350+ Million Series D Financing

PALO ALTO/SAN FRANCISCO/WASHINGTON— Covington advised Eikon Therapeutics, Inc., a biotechnology company, on its $350.7 million Series D financing. The financing round was led by Eikon’s existing investors, with participation from new investors. The investment syndicate is composed of top mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms including Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, Inc., and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others.